Increasing unusual option volume: ICLN JBHT ACIC GL RMD STLD CONL TRV

Go back to Increasing unusual option volume: ICLN JBHT ACIC GL RMD STLD CONL TRV

Travelers (TRV) PT Lowered to $225 at RBC Capital

April 18, 2024 6:21 AM EDT

RBC Capital analyst Mark Dwelle lowered the price target on Travelers (NYSE: TRV) to $225.00 (from $230.00) while maintaining a Sector Perform rating.

The analyst comments "Although Q1 results were impacted by larger-than-normal catastrophe losses, we viewed the overall y/y core margin improvement across... More

Travelers (TRV) PT Lowered to $202 at Goldman Sachs

April 17, 2024 3:48 PM EDT

Goldman Sachs analyst Alex Scott lowered the price target on Travelers (NYSE: TRV) to $202.00 (from $212.00) while maintaining a Sell rating.

The analyst comments "In our view, TRV's share price reaction today (-8% currently) reflects investor focus on additions to liability reserves for recent accident years in Business Insurance plus... More

Travelers (TRV) PT Lowered to $235 at CFRA

April 17, 2024 12:41 PM EDT

CFRA analyst Cathy Seifert lowered the price target on Travelers (NYSE: TRV) to $235.00 (from $240.00) while maintaining a Buy rating.

The analyst comments "We trim our 12-month target price by $5 to $235, valuing the shares at 11.3x our 2025 operating EPS estimate of $20.75 (raised by $0.80) and at... More

Travelers (TRV) PT Lowered to $214 at Morgan Stanley

April 17, 2024 12:28 PM EDT

Morgan Stanley analyst Bob Huang lowered the price target on Travelers (NYSE: TRV) to $214.00 (from $230.00) while maintaining a Equalweight rating.

The analyst comments "Elevated loss ratio in Business Insurance and elevated expenses in Bond & Specialty insurance drove the earnings miss. Slower than... More

Travelers (TRV) PT Raised to $220 at JPMorgan

April 17, 2024 9:57 AM EDT

JPMorgan analyst Jimmy Bhullar raised the price target on Travelers (NYSE: TRV) to $220.00 (from $213.00) while maintaining a Underweight rating.

The analyst comments "TRVs reported relatively healthy business trends in 1Q24, but earnings missed consensus projections (beat our forecast). Elevated cat losses offset... More